Nicholson Nur 4

What Happened
Nicholson Nur, Chief Technical Officer of Apellis Pharmaceuticals (APLS), sold 2,203 shares on January 20, 2026 at $19.79 per share, generating proceeds of $43,604. The filing shows this sale was to cover tax withholding on Restricted Stock Units (RSUs) that vested on January 16, 2026 — a routine disposition rather than a standalone investment decision.

Key Details

• Transaction date and price: 2026-01-20, 2,203 shares at $19.79 each (total $43,604)
• Transaction type: Sale (open market or private sale) executed to satisfy tax withholding obligations
• Footnote: Shares sold to cover tax withholding on RSUs released Jan 16, 2026 (Footnote F1)
• Shares owned after transaction: Not disclosed in the provided filing excerpt
• Filing timeliness: Report filed on Jan 21, 2026 (within normal Form 4 reporting window)

Context
Sales to cover tax withholding for vested RSUs are common and typically reflect routine administrative needs rather than a view on the company's prospects. For retail investors, purchases usually carry more signal value than routine withholding sales; this transaction should be viewed in that context.